TD Asset Management Inc Has $94.56 Million Stake in Pfizer Inc. $PFE

TD Asset Management Inc trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,927,083 shares of the biopharmaceutical company’s stock after selling 230,050 shares during the period. TD Asset Management Inc owned approximately 0.07% of Pfizer worth $94,564,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PFE. Brighton Jones LLC boosted its stake in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the last quarter. United Bank lifted its holdings in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the last quarter. Sei Investments Co. boosted its position in shares of Pfizer by 31.5% in the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC boosted its position in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

PFE opened at $27.30 on Wednesday. The stock’s 50 day simple moving average is $25.18 and its 200-day simple moving average is $26.21. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market cap of $155.57 billion, a PE ratio of 35.91 and a beta of 0.34. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same period last year, the business earned $0.78 earnings per share. Pfizer’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a report on Monday, July 6th. UBS Group restated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, May 27th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: EMA validates Lyme vaccine filing: The European Medicines Agency validated Pfizer and Valneva’s marketing application for their Lyme disease vaccine candidate, allowing the application to proceed to a full regulatory review. The filing follows late-stage data showing encouraging efficacy and safety. Approval could create a new commercial opportunity for Pfizer, although regulatory and launch risks remain. Pfizer Gets EMA Lyme Vaccine Filing Validation
• Positive Sentiment: Pipeline and intellectual-property support: Pfizer completed a Phase 1 study of its early-stage obesity candidate PF-08653944, maintaining optionality in a high-growth therapeutic market. A separate patent analysis also identified Pfizer as a leading holder of next-generation antibody-drug-conjugate patents, strengthening the company’s potential position in cancer treatment. Both developments are longer-term catalysts rather than immediate revenue drivers. Pfizer Advances Early Obesity Drug PF-08653944
• Neutral Sentiment: Healthcare-sector momentum: Healthcare indexes rose broadly late Tuesday, providing a favorable trading backdrop for defensive, dividend-paying pharmaceutical companies such as Pfizer. The sector move appears to be a market-wide factor rather than a Pfizer-specific fundamental change. Healthcare Stocks Climb Late Afternoon
• Neutral Sentiment: Obesity-drug competition and deal interest: Kailera Therapeutics’ large obesity-drug IPO highlights intense industry interest in the market and could increase attention on Pfizer’s pipeline or potential acquisition opportunities. At the same time, rising competition makes Pfizer’s early-stage program more speculative. Kailera Therapeutics Obesity IPO
• Negative Sentiment: Patent-cliff concerns remain: Despite Pfizer’s low valuation and attractive dividend, analysts continue to warn that upcoming patent expirations could pressure revenue and earnings as key products face generic or biosimilar competition. This remains the primary fundamental overhang on PFE. Pfizer Still Cheap Valuation Meets a Looming Patent Cliff

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.